

Spain Kidney Function Tests Market By Urine Tests (Urine Protein Tests, Creatinine Clearance Tests, Microalbumin Tests), By Blood Tests (Serum Creatinine Tests, Glomerular Filtration Rate Tests, Blood Urea Nitrogen Tests), By Component (Dipsticks, Reagents, Kits & Assays, Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, Others), By Region, Competition, Forecast & Opportunities, 2019-2029F

Market Report | 2024-12-13 | 85 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7000.00

Report description:

Spain Kidney Function Tests Market was valued at USD 10.71 million in 2023 and is expected to reach USD 15.12 million by 2029 with a CAGR of 7.74% through 2029. The Spain Kidney Function Tests Market is a crucial component of the country's healthcare industry, contributing to the diagnosis, monitoring, and treatment of kidney-related diseases and disorders. Kidney function tests, also known as renal function tests, assess the health and performance of the kidneys, helping healthcare professionals detect various kidney conditions and evaluate the efficiency of renal function.

Key Market Drivers

Rising Prevalence of Kidney Diseases

Spain, like many countries worldwide, is grappling with an alarming increase in kidney diseases. As the population ages and chronic health conditions such as diabetes and hypertension become more prevalent, the burden on kidney health has grown substantially.

Chronic Kidney Disease (CKD) has reached epidemic proportions in Spain. A significant portion of the population is affected, with millions of people living with various stages of kidney dysfunction. This surge can be attributed to factors such as an aging population, lifestyle-related health issues, and a genetic predisposition to kidney conditions. For instance, according to the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

National Library of Medicine, chronic kidney disease (CKD) is a global health issue that impacts around 15.1% of the general population in Spain as of 2023. However, most literature suggests that underdiagnosis may further elevate this prevalence. Kidney function tests have emerged as a critical diagnostic tool in addressing the growing challenge of kidney diseases. These tests encompass a range of assessments, including serum creatinine tests, estimated glomerular filtration rate (eGFR) tests, blood urea nitrogen (BUN) tests, and urinalysis, all of which provide valuable insights into kidney health. The increasing prevalence of kidney diseases necessitates regular testing for early detection, monitoring, and treatment.

One of the primary drivers of growth in the Spain Kidney Function Tests Market is the need for early diagnosis and effective management of kidney diseases. The rise in awareness about the benefits of timely detection has led to a higher demand for kidney function tests. Early diagnosis enables healthcare professionals to intervene at an earlier stage of the disease, potentially slowing its progression and reducing the overall healthcare cost burden.

Kidney diseases often accompany chronic conditions such as diabetes, hypertension, and cardiovascular diseases. Patients with these conditions are at a higher risk of kidney problems. As the prevalence of these chronic diseases continues to grow, regular kidney function testing becomes essential for monitoring kidney health and making necessary adjustments to treatment plans. In response to the rising prevalence of kidney diseases, individuals with risk factors, such as those with a family history of kidney issues or comorbid conditions, are increasingly seeking routine check-ups. This growing patient awareness is driving the demand for kidney function tests as a part of regular health assessments.

Emphasis on Early Detection

The emphasis on early detection of health issues has become a cornerstone of modern healthcare, and kidney diseases are no exception. In Spain, as in many parts of the world, kidney diseases are on the rise due to various factors. To address this growing concern, there has been a substantial shift towards early detection, significantly impacting the Spain Kidney Function Tests Market.

Spain has witnessed a concerning increase in kidney diseases, including Chronic Kidney Disease (CKD). The aging population, sedentary lifestyles, and the prevalence of risk factors such as diabetes and hypertension have contributed to this growing health challenge. Early detection of kidney diseases is crucial to mitigate their impact and improve patient outcomes. Kidney diseases are often asymptomatic in their early stages, making them difficult to diagnose without specific tests. However, early detection allows for timely intervention, which can significantly slow the progression of these conditions. This emphasis on early detection has the potential to save lives and reduce the overall economic burden of kidney diseases on the healthcare system.

Kidney function tests play a pivotal role in the early detection of kidney diseases. These tests include measures such as serum creatinine, estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), and urinalysis. They provide critical insights into kidney health, enabling healthcare professionals to identify issues at an early stage and initiate appropriate treatments. Early detection not only helps prevent the advancement of kidney diseases but also minimizes the risk of complications. Kidney diseases can lead to serious health issues, including cardiovascular problems, anemia, and bone disease. Detecting and addressing kidney problems at an early stage can reduce the likelihood of such complications and improve patients' quality of life. Healthcare policies in Spain have increasingly emphasized the importance of early detection in managing kidney diseases. This shift has been reinforced by educational campaigns aimed at healthcare providers and the general public. Knowledge about the benefits of early detection has empowered individuals to take proactive steps in monitoring their kidney health.

Increasing Healthcare Expenditure

In Spain, as in many developed nations, healthcare expenditure is on the rise. This increasing investment in healthcare is not only indicative of a commitment to improving public health but is also having a significant impact on various sectors within the healthcare industry. In 2021, public healthcare spending reached approximately USD 92.38 billion, accounting for 7.3% of the country's GDP. This investment underscores Spain's dedication to providing quality healthcare services to its citizens.

Spain's healthcare system has been the focus of increased investment in recent years. The government and private healthcare institutions have recognized the need to enhance healthcare services, modernize infrastructure, and improve access to diagnostics and treatment. This commitment to healthcare is a pivotal factor in the growth of the Spain Kidney Function Tests Market.

The surge in healthcare expenditure has enabled the acquisition and integration of cutting-edge medical technology in healthcare facilities across the country. This includes state-of-the-art diagnostic equipment and systems that enhance the accuracy and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

efficiency of kidney function tests. These technological advancements are making it easier for healthcare providers to diagnose kidney diseases and monitor patients' kidney health.

Increased healthcare spending has led to the expansion of healthcare facilities, including clinics, hospitals, and laboratories. This growth in infrastructure has made healthcare services, including kidney function tests, more accessible to a larger portion of the population. Enhanced access to these tests is a fundamental driver of their increased utilization.

With more resources at their disposal, healthcare providers in Spain are shifting their focus from reactive care to preventive healthcare. Preventive measures, including routine check-ups and early diagnosis, are now central to healthcare strategies. Kidney function tests are a critical component of this preventive approach, enabling the timely detection of kidney diseases. Investment in healthcare can also be seen as a strategy to reduce the economic burden of treating advanced-stage kidney diseases. By identifying and managing kidney conditions at an early stage, the cost of healthcare for both patients and the healthcare system is considerably reduced. Early diagnosis through kidney function tests is a cost-effective approach to healthcare.

Rising healthcare spending has allowed for the ongoing education and training of healthcare professionals. This ensures that they are well-equipped to use the latest medical technology and diagnostic procedures, including kidney function tests.

Integration of Point-of-Care Testing

Point-of-care testing (POCT) has revolutionized the landscape of healthcare diagnostics, offering rapid and convenient testing at or near the patient's location. In Spain, the integration of point-of-care testing has become a game-changer in the healthcare industry, and the Spain Kidney Function Tests Market is no exception.

Point-of-care testing has redefined healthcare delivery by bringing diagnostics closer to the patient. In Spain, this technology has experienced significant adoption in various medical fields, including kidney function testing. Point-of-care testing for kidney function allows for quicker assessment, immediate decision-making, and more timely intervention.

One of the primary benefits of point-of-care kidney function testing is the rapid turnaround time for results. In critical healthcare situations, such as emergency departments or intensive care units, quick access to kidney function data is essential. POCT eliminates the delay associated with sending samples to a central laboratory, allowing healthcare providers to make immediate decisions.

The integration of point-of-care testing makes kidney function tests more accessible and convenient for patients. These tests can be performed in a variety of healthcare settings, including doctors' offices, clinics, and even at the patient's bedside. This convenience encourages patients to undergo regular kidney function testing as part of their healthcare routine.

Patients with chronic conditions, such as diabetes and hypertension, often require ongoing monitoring of their kidney function. Point-of-care testing simplifies the process, enabling healthcare providers to regularly check their patients' kidney health during routine appointments. This proactive approach helps manage chronic conditions effectively.

Kidney diseases can lead to various complications, including cardiovascular issues, anemia, and bone disease. By integrating point-of-care kidney function tests into regular patient care, healthcare providers can detect kidney problems at an early stage, minimizing the risk of such complications and improving overall patient outcomes.

Point-of-care testing is particularly valuable in reaching underserved and remote areas in Spain. Patients in rural or distant regions often face challenges accessing healthcare facilities. With portable testing equipment, healthcare professionals can bring kidney function testing to these areas, improving healthcare equity.

Key Market Challenges

Regional Disparities

Regional disparities pose a significant challenge in the Spain Kidney Function Tests market, driven by variations in healthcare infrastructure, resource allocation, and accessibility. Urban centers such as Madrid and Barcelona typically offer advanced diagnostic technologies and specialized nephrology services, ensuring timely and accurate kidney function assessments. In contrast, rural and remote areas often lack sufficient healthcare facilities and trained personnel, creating a gap in service delivery. This disparity can result in delayed diagnoses and treatment, worsening patient outcomes in underserved regions.

Economic inequalities further exacerbate this issue. Regions with lower socioeconomic development face difficulties in funding and maintaining modern diagnostic equipment, limiting the availability of advanced testing methods like Plasma Clearance of Iohexol or eGFR meters. Public healthcare systems in these areas may prioritize other critical services over the integration of

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

specialized kidney diagnostic solutions.

Logistical challenges also contribute to regional discrepancies. Transporting samples from remote areas to central laboratories for analysis can delay test results and impact clinical decisions. This situation underscores the need for portable or point-of-care diagnostic devices that can perform accurate kidney function tests in decentralized locations.

High Costs of Advanced Testing

The high costs associated with advanced kidney function testing present a significant challenge in the Spain kidney function tests market. Many innovative diagnostic techniques, such as the use of biomarkers or advanced imaging, require sophisticated equipment, specialized reagents, and highly trained personnel, all of which contribute to increased expenses. These costs can deter smaller healthcare providers, particularly in rural or underfunded areas, from adopting cutting-edge technologies, limiting access to accurate and early diagnosis for patients. Additionally, private healthcare facilities may face challenges in balancing operational costs and competitive pricing, especially as reimbursement policies for advanced diagnostics remain inconsistent. The economic burden on public healthcare systems further exacerbates this issue. Public hospitals, which cater to a large portion of the population, often struggle to allocate budgets for high-cost diagnostic tools, especially when managing multiple priorities such as chronic diseases and aging populations. Patients in low-income groups may also find advanced kidney tests financially inaccessible, leading to delayed diagnoses and poorer outcomes. The high upfront investment required to adopt these technologies, combined with the lack of scalable solutions, restricts widespread implementation, particularly in areas outside metropolitan regions.

These challenges create a gap in market growth potential, where demand for affordable yet accurate testing solutions remains unmet. Stakeholders, including diagnostic companies and policymakers, face pressure to develop cost-effective methods or introduce subsidization models to address these barriers. The necessity for strategic initiatives to reduce costs while maintaining high diagnostic standards is paramount for ensuring broader accessibility and equity in healthcare across Spain.

Key Market Trends

Biomarker Innovation

The Spain kidney function tests market is experiencing a shift toward biomarker innovation, driven by the demand for accurate, early detection and personalized treatment approaches for kidney diseases. Biomarkers offer a non-invasive and reliable means of assessing renal function and detecting early-stage kidney disorders, which is critical given the rising prevalence of chronic kidney disease (CKD) and other renal conditions in the country. Research institutions and healthcare organizations are collaborating to develop novel biomarkers that can detect subtle changes in kidney function before significant damage occurs. These innovations include emerging technologies such as plasma clearance methods, proteomics, and genomics-based biomarkers that provide deeper insights into renal physiology and pathology.

Diagnostic companies are integrating advanced biomarker panels into next-generation testing platforms, combining them with digital health tools for improved data analysis and patient monitoring. This integration facilitates real-time clinical decision-making and supports value-based healthcare models. Regulatory frameworks in Spain, aligned with the European Union's Medical Device Regulation (MDR), encourage the adoption of cutting-edge diagnostic technologies while ensuring safety and efficacy. The increasing use of point-of-care (POC) devices equipped with biomarker capabilities is enabling broader access to kidney function testing in community settings, reducing the burden on centralized laboratories.

Pharmaceutical companies are also leveraging biomarker advancements to optimize drug development processes, particularly in the nephrology sector, enhancing the effectiveness of therapeutic interventions. Public and private funding initiatives are fueling research and commercialization efforts in this domain. The growing awareness among healthcare professionals and patients about the importance of early kidney function assessment is accelerating market adoption. This trend underscores a transformative phase in the kidney function tests market in Spain, with biomarker innovation playing a pivotal role in improving diagnostic accuracy, enhancing patient outcomes, and driving sustainable healthcare solutions.

Artificial Kidneys and Organoids

The Spain kidney function tests market is witnessing a transformative trend driven by advancements in artificial kidneys and organoid technology. Artificial kidneys, a revolutionary approach to managing kidney failure, are being developed as compact, wearable, or implantable devices that replicate the filtration functions of natural kidneys. These innovations aim to provide a long-term alternative to dialysis, offering improved quality of life for patients. Research and clinical trials in Spain have shown

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

promising progress, with collaborations between medical institutions and biotechnology firms accelerating the development of these devices. The adoption of artificial kidneys is expected to reshape patient care by reducing dependency on traditional dialysis and addressing the scarcity of donor organs.

Organoids, lab-grown miniature versions of human kidneys, are emerging as a critical tool for understanding kidney diseases and testing therapies. These 3D structures, derived from patient-specific stem cells, mimic the architecture and functionality of natural kidneys, enabling researchers to study complex disease mechanisms in a controlled environment. In Spain, organoid research has gained traction, supported by academic institutions and research grants, fostering innovation in personalized medicine. Organoids also hold potential in drug discovery, allowing pharmaceutical companies to evaluate the safety and efficacy of new treatments with greater precision.

The integration of artificial kidneys and organoid technology into the kidney function tests market is transforming diagnostic and therapeutic approaches. These advancements enhance the ability to monitor kidney health, predict disease progression, and tailor interventions to individual needs. Spain's proactive stance in adopting these technologies, coupled with a supportive regulatory framework, positions the country as a hub for innovation in nephrology. The convergence of these trends underscores a paradigm shift toward more sustainable, patient-centric solutions in managing kidney health and addressing the growing burden of chronic kidney disease.

Segmental Insights

Urine Tests Insights

Based on Urine Tests, Creatinine Clearance Tests are poised to dominate the Kidney Function Tests Market in Spain. Firstly, they provide a comprehensive assessment of renal function by measuring the glomerular filtration rate (GFR), which is considered the gold standard in assessing kidney health. This accuracy is crucial in diagnosing and monitoring conditions like chronic kidney disease. Secondly, Creatinine Clearance Tests are relatively simple, cost-effective, and easily accessible, making them an attractive option for both healthcare providers and patients. Also, as the population ages and the prevalence of kidney-related disorders increases, the demand for reliable kidney function assessments is growing. Given these advantages, it is likely that Creatinine Clearance Tests will continue to gain prominence and market share in Spain's Kidney Function Tests Market, as they offer an efficient and accurate solution for evaluating renal health.

Component Insights

Based on Component, Dipsticks are positioned to dominate as a component in the Spain Kidney Function Tests Market. Firstly, dipsticks offer a quick and cost-effective means of screening for kidney function abnormalities. Their simplicity and user-friendliness make them an attractive choice for routine testing, both in clinical settings and for home use. Dipstick tests can efficiently detect key biomarkers such as creatinine and protein in urine, allowing for early detection of kidney-related issues. Additionally, the rising prevalence of chronic kidney disease and the need for regular monitoring among patients further drive the demand for efficient and accessible testing methods. Given these advantages, dipsticks are expected to continue their dominance as a preferred component in the Spain Kidney Function Tests Market, providing a convenient and reliable solution for assessing renal health.

Regional Insights

The Central Region in North Spain is poised to dominate the Kidney Function Tests Market. Firstly, it serves as a healthcare hub, with a concentration of leading hospitals, clinics, and medical facilities known for their advanced diagnostic services. These institutions often lead the way in adopting the latest technologies and methodologies for kidney function testing, making the Central Region a center of excellence in this field. Additionally, the region's demographic composition, characterized by a higher proportion of elderly individuals, contributes to a growing demand for kidney function assessments. Moreover, the Central Region's strong infrastructure and accessibility make it a convenient location for patients from surrounding areas, further bolstering its prominence in the market. Overall, the combination of top-tier healthcare facilities, a significant patient population, and accessibility positions the Central Region in North Spain as a dominant force in the Kidney Function Tests Market.

Key Market Players

□□Baxter SL

□□Abbott Laboratories, S.A.

□□Sysmex Espana S.L.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Danaher Corporation
- Roche Diagnostics S.L.
- Nova Biomedical Corporation
- Siemens Healthineers Espana
- ARKRAY Espana S.A.U.
- Fresenius Medical Care Espana, S.A.U.
- Laboratorios Randox S.L.

Report Scope:

In this report, the Spain Kidney Function Tests Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

□□ Spain Kidney Function Tests Market, By Urine Tests:

- o Urine Protein Tests
- o Creatinine Clearance Tests
- o Microalbumin Tests

□□ Spain Kidney Function Tests Market, By Blood Tests:

- o Serum Creatinine Tests
- o Glomerular Filtration Rate Tests
- o Blood Urea Nitrogen Tests

□□ Spain Kidney Function Tests Market, By Component:

- o Dipsticks
- o Reagents
- o Kits & Assays
- o Others

□□ Spain Kidney Function Tests Market, By End User:

- o Hospitals & Clinics
- o Diagnostic Laboratories
- o Others

□□ Spain Kidney Function Tests Market, By Region:

- o Central Region North Spain
- o Aragon & Catalonia
- o Andalusia, Murcia & Valencia
- o Madrid, Extremadura & Castilla

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Spain Kidney Function Tests Market.

Available Customizations:

Spain Kidney Function Tests market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

- Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2. Research Methodology
 - 2.1. Objective of the Study
 - 2.2. Baseline Methodology
 - 2.3. Key Industry Partners
 - 2.4. Major Association and Secondary Sources
 - 2.5. Forecasting Methodology
 - 2.6. Data Triangulation & Validation
 - 2.7. Assumptions and Limitations
3. Executive Summary
 - 3.1. Overview of the Market
 - 3.2. Overview of Key Market Segmentations
 - 3.3. Overview of Key Market Players
 - 3.4. Overview of Key Regions/Countries
 - 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Spain Kidney Function Tests Market Outlook
 - 5.1. Market Size & Forecast
 - 5.1.1. By Value
 - 5.2. Market Share & Forecast
 - 5.2.1. By Urine Tests (Urine Protein Tests, Creatinine Clearance Tests, Microalbumin Tests)
 - 5.2.2. By Blood Tests (Serum Creatinine Tests, Glomerular Filtration Rate Tests, Blood Urea Nitrogen Tests)
 - 5.2.3. By Component (Dipsticks, Reagents, Kits & Assays, Others)
 - 5.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
 - 5.2.5. By Region
 - 5.2.6. By Company (2023)
 - 5.3. Market Map
 - 5.3.1. By Urine Tests
 - 5.3.2. By Blood Tests
 - 5.3.3. By Component
 - 5.3.4. By End User
 - 5.3.5. By Region
6. Central Region North Spain Kidney Function Tests Market Outlook
 - 6.1. Market Size & Forecast
 - 6.1.1. By Value
 - 6.2. Market Share & Forecast
 - 6.2.1. By Urine Tests (Urine Protein Tests, Creatinine Clearance Tests, Microalbumin Tests)
 - 6.2.2. By Blood Tests (Serum Creatinine Tests, Glomerular Filtration Rate Tests, Blood Urea Nitrogen Tests)
 - 6.2.3. By Component (Dipsticks, Reagents, Kits & Assays, Others)
 - 6.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
7. Aragon & Catalonia Kidney Function Tests Market Outlook
 - 7.1. Market Size & Forecast
 - 7.1.1. By Value
 - 7.2. Market Share & Forecast
 - 7.2.1. By Urine Tests (Urine Protein Tests, Creatinine Clearance Tests, Microalbumin Tests)
 - 7.2.2. By Blood Tests (Serum Creatinine Tests, Glomerular Filtration Rate Tests, Blood Urea Nitrogen Tests)
 - 7.2.3. By Component (Dipsticks, Reagents, Kits & Assays, Others)
 - 7.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8. Andalusia, Murcia & Valencia Kidney Function Tests Market Outlook
 - 8.1. Market Size & Forecast
 - 8.1.1. By Value
 - 8.2. Market Share & Forecast
 - 8.2.1. By Urine Tests (Urine Protein Tests, Creatinine Clearance Tests, Microalbumin Tests)
 - 8.2.2. By Blood Tests (Serum Creatinine Tests, Glomerular Filtration Rate Tests, Blood Urea Nitrogen Tests)
 - 8.2.3. By Component (Dipsticks, Reagents, Kits & Assays, Others)
 - 8.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
9. Madrid, Extremadura & Castilla Kidney Function Tests Market Outlook
 - 9.1. Market Size & Forecast
 - 9.1.1. By Value
 - 9.2. Market Share & Forecast
 - 9.2.1. By Urine Tests (Urine Protein Tests, Creatinine Clearance Tests, Microalbumin Tests)
 - 9.2.2. By Blood Tests (Serum Creatinine Tests, Glomerular Filtration Rate Tests, Blood Urea Nitrogen Tests)
 - 9.2.3. By Component (Dipsticks, Reagents, Kits & Assays, Others)
 - 9.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
10. Market Dynamics
 - 10.1. Drivers
 - 10.2. Challenges
11. Market Trends & Developments
 - 11.1. Recent Developments
 - 11.2. Mergers & Acquisitions
 - 11.3. Product Launches
12. Policy & Regulatory Landscape
13. Porter's Five Forces Analysis
 - 13.1. Competition in the Industry
 - 13.2. Potential of New Entrants
 - 13.3. Power of Suppliers
 - 13.4. Power of Customers
 - 13.5. Threat of Substitute Products
14. Spain Economic Profile
15. Competitive Landscape
 - 15.1. Baxter SL
 - 15.1.1. Business Overview
 - 15.1.2. Product Offerings
 - 15.1.3. Recent Developments
 - 15.1.4. Financials (As Reported)
 - 15.1.5. Key Personnel
 - 15.1.6. SWOT Analysis
 - 15.2. Abbott Laboratories, S.A.
 - 15.3. Sysmex Espana S.L.
 - 15.4. Danaher Corporation
 - 15.5. Roche Diagnostics S.L.
 - 15.6. Nova Biomedical Corporation
 - 15.7. Siemens Healthineers Espana
 - 15.8. ARKRAY Espana S.A.U.
 - 15.9. Fresenius Medical Care Espana, S.A.U.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.10. Laboratorios Randox S.L.
- 16. Strategic Recommendations
- 17. About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Spain Kidney Function Tests Market By Urine Tests (Urine Protein Tests, Creatinine Clearance Tests, Microalbumin Tests), By Blood Tests (Serum Creatinine Tests, Glomerular Filtration Rate Tests, Blood Urea Nitrogen Tests), By Component (Dipsticks, Reagents, Kits & Assays, Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, Others), By Region, Competition, Forecast & Opportunities, 2019-2029F

Market Report | 2024-12-13 | 85 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00
	Custom Research License	\$7000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-08"/>
		Signature	<input type="text"/>